{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T22:36:07Z","timestamp":1764714967779,"version":"3.44.0"},"reference-count":89,"publisher":"Elsevier","isbn-type":[{"type":"print","value":"9780128211663"}],"license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.1016\/bs.acc.2019.11.002","type":"book-chapter","created":{"date-parts":[[2020,3,3]],"date-time":"2020-03-03T07:59:54Z","timestamp":1583222394000},"page":"19-53","source":"Crossref","is-referenced-by-count":9,"title":["New biomarkers in non-Hodgkin lymphoma and acute leukemias"],"prefix":"10.1016","member":"78","reference":[{"issue":"1","key":"10.1016\/bs.acc.2019.11.002_bb9010","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000338393","article-title":"Tumor markers in clinical practice: a review focusing on common solid cancers","volume":"22","author":"Duffy","year":"2013","journal-title":"Med. Princ. Pract."},{"key":"10.1016\/bs.acc.2019.11.002_bb9015","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1146\/annurev-med-070912-143853","article-title":"Molecular testing in breast cancer","volume":"65","author":"Paoletti","year":"2014","journal-title":"Annu. Rev. Med."},{"issue":"4","key":"10.1016\/bs.acc.2019.11.002_bb9020","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S0889-8588(05)70318-X","article-title":"Prognostic factors for hematologic cancers","volume":"14","author":"Misra","year":"2000","journal-title":"Hematol. Oncol. Clin. North Am."},{"issue":"3","key":"10.1016\/bs.acc.2019.11.002_bb9025","first-page":"256","article-title":"Cancer biomarker discovery and validation","volume":"4","author":"Goossens","year":"2015","journal-title":"Transl. Cancer Res."},{"issue":"9","key":"10.1016\/bs.acc.2019.11.002_bb9030","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1056\/NEJMp1500523","article-title":"A new initiative on precision medicine","volume":"372","author":"Collins","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2019.11.002_bb9035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-319-13150-4_1","article-title":"Epidemiology and etiology of non-hodgkin lymphoma","volume":"165","author":"Chiu","year":"2015","journal-title":"Cancer Treat. Res."},{"issue":"1","key":"10.1016\/bs.acc.2019.11.002_bb9040","first-page":"5","article-title":"Cancer statistics, 2015","volume":"65","author":"Siegel","year":"2015","journal-title":"CA Cancer J. Clin."},{"issue":"6","key":"10.1016\/bs.acc.2019.11.002_bb9045","doi-asserted-by":"crossref","first-page":"785","DOI":"10.3904\/kjim.2014.29.6.785","article-title":"Clinical significance of nuclear factor kappaB and chemokine receptor CXCR4 expression in patients with diffuse large B-cell lymphoma who received rituximab-based therapy","volume":"29","author":"Shin","year":"2014","journal-title":"Korean J. Intern. Med."},{"issue":"6","key":"10.1016\/bs.acc.2019.11.002_bb9050","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.clml.2014.05.002","article-title":"Evaluating cell-of-origin subtype methods for predicting diffuse large B-cell lymphoma survival: a meta-analysis of gene expression profiling and immunohistochemistry algorithms","volume":"14","author":"Read","year":"2014","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"3","key":"10.1016\/bs.acc.2019.11.002_bb9055","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s11899-015-0267-0","article-title":"To each its own: linking the biology and epidemiology of NHL subtypes","volume":"10","author":"Koff","year":"2015","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/bs.acc.2019.11.002_bb9060","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.semcancer.2017.08.008","article-title":"Charting the dynamic epigenome during B-cell development","volume":"51","author":"Martin-Subero","year":"2018","journal-title":"Semin. Cancer Biol."},{"issue":"4","key":"10.1016\/bs.acc.2019.11.002_bb9065","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/13543776.2019.1594777","article-title":"Bruton's tyrosine kinase (BTK) inhibitors in treating cancer: a patent review (2010\u20132018)","volume":"29","author":"Feng","year":"2019","journal-title":"Expert Opin. Ther. Pat."},{"issue":"9844","key":"10.1016\/bs.acc.2019.11.002_bb9070","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S0140-6736(12)60605-9","article-title":"Non-Hodgkin lymphoma","volume":"380","author":"Shankland","year":"2012","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/bs.acc.2019.11.002_bb9075","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1007\/s00277-014-2116-y","article-title":"Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy","volume":"93","author":"Carbone","year":"2014","journal-title":"Ann. Hematol."},{"issue":"24","key":"10.1016\/bs.acc.2019.11.002_bb9080","doi-asserted-by":"crossref","first-page":"4795","DOI":"10.1182\/blood-2012-07-440073","article-title":"Classification of non-Hodgkin lymphoma in Central and South America: a review of 1028 cases","volume":"120","author":"Laurini","year":"2012","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/bs.acc.2019.11.002_bb9085","doi-asserted-by":"crossref","first-page":"S168","DOI":"10.1016\/j.canep.2016.05.008","article-title":"The burden of non-Hodgkin lymphoma in Central and South America","volume":"44","author":"Diumenjo","year":"2016","journal-title":"Cancer Epidemiol."},{"issue":"14","key":"10.1016\/bs.acc.2019.11.002_bb9090","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin's lymphoma","volume":"329","author":"International Non-Hodgkin's Lymphoma Prognostic Factors Project","year":"1993","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/bs.acc.2019.11.002_bb9095","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","article-title":"The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"109","author":"Sehn","year":"2007","journal-title":"Blood"},{"issue":"10","key":"10.1016\/bs.acc.2019.11.002_bb9100","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1080\/10428194.2019.1587755","article-title":"The prognostic significance of bone marrow involvement in diffuse large B cell lymphoma according to the flow cytometry","volume":"60","author":"Greenbaum","year":"2019","journal-title":"Leuk. Lymphoma"},{"issue":"11","key":"10.1016\/bs.acc.2019.11.002_bb9105","doi-asserted-by":"crossref","first-page":"e1251","DOI":"10.1634\/theoncologist.2018-0361","article-title":"Prognostic nomogram for overall survival in patients with diffuse large B-cell lymphoma","volume":"24","author":"Han","year":"2019","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/bs.acc.2019.11.002_bb9110","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1182\/blood-2013-09-524108","article-title":"An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era","volume":"123","author":"Zhou","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/bs.acc.2019.11.002_bb9115","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1365-2141.2010.08331.x","volume":"151","author":"Advani","year":"2010","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/bs.acc.2019.11.002_bb9120","doi-asserted-by":"crossref","first-page":"292","DOI":"10.5301\/tj.5000694","article-title":"A new prognostic model using the NCCN-IPI and neutrophil-to-lymphocyte ratio in diffuse large B-cell lymphoma","volume":"104","author":"Go","year":"2018","journal-title":"Tumori."},{"key":"10.1016\/bs.acc.2019.11.002_bb9125","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ebiom.2019.02.048","article-title":"Prognostic nomogram incorporating inflammatory cytokines for overall survival in patients with aggressive non-Hodgkin's lymphoma","volume":"41","author":"Zhong","year":"2019","journal-title":"EBioMedicine."},{"issue":"8","key":"10.1016\/bs.acc.2019.11.002_bb9130","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1007\/s00277-019-03676-0","article-title":"Clinical risk scores do not accurately identify a very high risk population with diffuse large B cell lymphoma-an analysis of 386 Portuguese patients","volume":"98","author":"Coutinho","year":"2019","journal-title":"Ann. Hematol."},{"issue":"6","key":"10.1016\/bs.acc.2019.11.002_bb9135","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/bjh.14489","article-title":"Validation of the NCCN-IPI for diffuse large B-cell lymphoma (DLBCL): the addition of beta2 -microglobulin yields a more accurate GELTAMO-IPI","volume":"176","author":"Montalban","year":"2017","journal-title":"Br. J. Haematol."},{"issue":"11","key":"10.1016\/bs.acc.2019.11.002_bb9140","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.clml.2015.07.639","article-title":"Prognostic value of anemia and C-reactive protein levels in diffuse large B-Cell lymphoma","volume":"15","author":"Adams","year":"2015","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"6","key":"10.1016\/bs.acc.2019.11.002_bb9145","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/ejh.12529","article-title":"The significance of pretreatment anemia in the era of R-IPI and NCCN-IPI prognostic risk assessment tools: a dual-center study in diffuse large B-cell lymphoma patients","volume":"95","author":"Troppan","year":"2015","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/bs.acc.2019.11.002_bb9150","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1155\/2018\/2891093","article-title":"A novel scoring system based on the level of HDL-C for predicting the prognosis of t-DLBCL patients: a single retrospective study","volume":"2018","author":"Xu","year":"2018","journal-title":"Biomed. Res. Int."},{"issue":"5\u20136","key":"10.1016\/bs.acc.2019.11.002_bb9155","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1080\/08830180701703364","article-title":"NF-kappaB in pathogenesis and treatment of adult T-cell leukemia\/lymphoma","volume":"26","author":"Horie","year":"2007","journal-title":"Int. Rev. Immunol."},{"issue":"3","key":"10.1016\/bs.acc.2019.11.002_bb9160","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/path.2864","article-title":"The biological and clinical impact of inhibition of NF-kappaB-initiated apoptosis in diffuse large B cell lymphoma (DLBCL). The","volume":"224","author":"Bavi","year":"2011","journal-title":"J. Pathol."},{"issue":"2","key":"10.1016\/bs.acc.2019.11.002_bb9165","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/cells5020016","article-title":"The NF-kappaB pathway and cancer stem cells","volume":"5","author":"Rinkenbaugh","year":"2016","journal-title":"Cells"},{"key":"10.1016\/bs.acc.2019.11.002_bb9170","doi-asserted-by":"crossref","DOI":"10.1186\/s40364-016-0067-2","article-title":"The CXCR4 antagonist plerixafor enhances the effect of rituximab in diffuse large B-cell lymphoma cell lines","volume":"4","author":"Reinholdt","year":"2016","journal-title":"Biomarker Res."},{"issue":"13","key":"10.1016\/bs.acc.2019.11.002_bb9175","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1158\/1078-0432.CCR-12-3015","article-title":"Targeting the CD20 and CXCR4 pathways in non-hodgkin lymphoma with rituximab and high-affinity CXCR4 antagonist BKT140","volume":"19","author":"Beider","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"17","key":"10.1016\/bs.acc.2019.11.002_bb9180","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.2217\/fon.15.144","article-title":"Next-generation prognostic assessment for diffuse large B-cell lymphoma","volume":"11","author":"Staton","year":"2015","journal-title":"Future Oncol."},{"issue":"5","key":"10.1016\/bs.acc.2019.11.002_bb9185","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1158\/2159-8290.CD-15-0011","article-title":"The BCL2 family: key mediators of the apoptotic response to targeted anticancer therapeutics","volume":"5","author":"Hata","year":"2015","journal-title":"Cancer Discov."},{"issue":"5\u20136","key":"10.1016\/bs.acc.2019.11.002_bb9190","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/08830180701655945","article-title":"Transcription factors as therapeutic targets in lymphoid malignancies","volume":"26","author":"Sanda","year":"2007","journal-title":"Int. Rev. Immunol."},{"issue":"3","key":"10.1016\/bs.acc.2019.11.002_bb9195","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3960\/jslrt.53.185","article-title":"Molecularly-targeted strategy and NF-kappaB in lymphoid malignancies","volume":"53","author":"Horie","year":"2013","journal-title":"J. Clin. Exp. Hematop."},{"issue":"1","key":"10.1016\/bs.acc.2019.11.002_bb9200","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1600-065X.2012.01105.x","article-title":"Pathogenetic importance and therapeutic implications of NF-kappaB in lymphoid malignancies","volume":"246","author":"Lim","year":"2012","journal-title":"Immunol. Rev."},{"issue":"9","key":"10.1016\/bs.acc.2019.11.002_bb9205","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/cbin.10631","article-title":"CXCR4 and CCR7: two eligible targets in targeted cancer therapy","volume":"40","author":"Mishan","year":"2016","journal-title":"Cell Biol. Int."},{"issue":"5","key":"10.1016\/bs.acc.2019.11.002_bb9210","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0098194","article-title":"Decreased expression of CXCR4 chemokine receptor in bone marrow after chemotherapy in patients with non-Hodgkin lymphomas is a good prognostic factor","volume":"9","author":"Mazur","year":"2014","journal-title":"PloS one."},{"issue":"8","key":"10.1016\/bs.acc.2019.11.002_bb9215","doi-asserted-by":"crossref","first-page":"5597","DOI":"10.18632\/oncotarget.3343","article-title":"Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma","volume":"6","author":"Chen","year":"2015","journal-title":"Oncotarget."},{"issue":"3","key":"10.1016\/bs.acc.2019.11.002_bb9220","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/PAS.0b013e3181cd3aeb","article-title":"B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma","volume":"34","author":"Snuderl","year":"2010","journal-title":"Am. J. Surg. Pathol."},{"issue":"36","key":"10.1016\/bs.acc.2019.11.002_bb9225","article-title":"MYC-driven aggressive B-cell lymphomas: biology, entity","volume":"6","author":"Cai","year":"2015","journal-title":"differential diagnosis and clinical management. Oncotarget"},{"issue":"3","key":"10.1016\/bs.acc.2019.11.002_bb9230","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.18632\/oncotarget.6262","article-title":"Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma","volume":"7","author":"Ye","year":"2016","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/bs.acc.2019.11.002_bb9235","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/cncr.29781","article-title":"Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma","volume":"122","author":"Landsburg","year":"2016","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/bs.acc.2019.11.002_bb9240","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-016-0571-x","article-title":"Targeting acute myeloid leukemia stem cell signaling by natural products","volume":"16","author":"Siveen","year":"2017","journal-title":"Mol. Cancer"},{"issue":"12","key":"10.1016\/bs.acc.2019.11.002_bb9245","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","article-title":"Prognostic relevance of integrated genetic profiling in acute myeloid leukemia","volume":"366","author":"Patel","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2019.11.002_bb9250","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/asheducation-2015.1.579","article-title":"Molecularly targeted therapies for acute myeloid leukemia","volume":"2015","author":"Stein","year":"2015","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"issue":"12","key":"10.1016\/bs.acc.2019.11.002_bb9255","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"Dohner","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/bs.acc.2019.11.002_bb9260","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2015-08-604520","article-title":"An update of current treatments for adult acute myeloid leukemia","volume":"127","author":"Dombret","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/bs.acc.2019.11.002_bb9265","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/asheducation.V2014.1.34.3882398","article-title":"Intermediate-risk acute myeloid leukemia therapy: current and future","volume":"2014","author":"Dohner","year":"2014","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"issue":"1","key":"10.1016\/bs.acc.2019.11.002_bb9270","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1182\/blood-2015-07-604512","article-title":"Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia","volume":"127","author":"Wouters","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/bs.acc.2019.11.002_bb9275","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ccr.2010.01.020","article-title":"The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate","volume":"17","author":"Ward","year":"2010","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1016\/bs.acc.2019.11.002_bb9280","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1200\/JCO.2010.32.7742","article-title":"TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study","volume":"29","author":"Metzeler","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/bs.acc.2019.11.002_bb9285","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/ajh.24246","article-title":"Acute myeloid leukemia\u2014major progress over four decades and glimpses into the future","volume":"91","author":"Kantarjian","year":"2016","journal-title":"Am. J. Hematol."},{"issue":"23","key":"10.1016\/bs.acc.2019.11.002_bb9290","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/bs.acc.2019.11.002_bb9295","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood-2015-07-604496","article-title":"Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance","volume":"127","author":"Grimwade","year":"2016","journal-title":"Blood"},{"issue":"7","key":"10.1016\/bs.acc.2019.11.002_bb9300","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1182\/blood-2015-09-666560","article-title":"Not only TKI! Targeting FLT3-ITD by autophagy","volume":"127","author":"Marcucci","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/bs.acc.2019.11.002_bb9310","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1182\/asheducation-2014.1.44","article-title":"Epigenetic targeting and personalized approaches for AML","volume":"2014","author":"Roboz","year":"2014","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/bs.acc.2019.11.002_bb9315","series-title":"World Health Organization classification of tumours International Agency for Research on Cancer Press, Lyon","article-title":"Pathology and Genetics of Tumours of Hematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008"},{"issue":"9","key":"10.1016\/bs.acc.2019.11.002_bb9320","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","article-title":"Acute myeloid leukemia ontogeny is defined by distinct somatic mutations","volume":"125","author":"Lindsley","year":"2015","journal-title":"Blood"},{"issue":"23","key":"10.1016\/bs.acc.2019.11.002_bb9325","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1182\/blood-2014-05-577593","article-title":"Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for \u201cprime time\u201d?","volume":"124","author":"Grimwade","year":"2014","journal-title":"Blood"},{"issue":"15","key":"10.1016\/bs.acc.2019.11.002_bb9330","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1182\/blood-2014-11-578815","article-title":"Minimal residual disease-directed therapy in acute myeloid leukemia","volume":"125","author":"Kayser","year":"2015","journal-title":"Blood"},{"issue":"3","key":"10.1016\/bs.acc.2019.11.002_bb9335","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.beha.2013.10.003","article-title":"Molecular pathogenesis of AML: translating insights to the clinic","volume":"26","author":"Levine","year":"2013","journal-title":"Best Pract. Res. Clin. Haematol."},{"issue":"6","key":"10.1016\/bs.acc.2019.11.002_bb9340","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/bjh.13912","article-title":"TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation","volume":"172","author":"Middeke","year":"2016","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/bs.acc.2019.11.002_bb9345","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood-2015-07-604538","article-title":"Emerging therapeutic drugs for AML","volume":"127","author":"Stein","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/bs.acc.2019.11.002_bb9350","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.cell.2014.02.019","article-title":"A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia","volume":"157","author":"Groschel","year":"2014","journal-title":"Cell"},{"issue":"7370","key":"10.1016\/bs.acc.2019.11.002_bb9355","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nature10509","article-title":"Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia","volume":"478","author":"Dawson","year":"2011","journal-title":"Nature"},{"issue":"6","key":"10.1016\/bs.acc.2019.11.002_bb9360","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1111\/bjh.13898","article-title":"Review: aberrant EVI1 expression in acute myeloid leukaemia","volume":"172","author":"Hinai","year":"2016","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/bs.acc.2019.11.002_bb9365","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3324\/haematol.2015.141101","article-title":"New and emerging prognostic and predictive genetic biomarkers in B-cell precursor acute lymphoblastic leukemia","volume":"101","author":"Moorman","year":"2016","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/bs.acc.2019.11.002_bb9370","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2014.052","article-title":"Treatment of adolescent and young adults with acute lymphoblastic leukemia","volume":"6","author":"Ribera","year":"2014","journal-title":"Mediterr J Hematol Infect Dis."},{"key":"10.1016\/bs.acc.2019.11.002_bb9375","first-page":"371","article-title":"Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia","volume":"24","author":"Pui","year":"2009","journal-title":"Leuk. Off. J. Leuk. Soc. Am. Leuk. Res. Fund UK."},{"issue":"21","key":"10.1016\/bs.acc.2019.11.002_bb9380","doi-asserted-by":"crossref","first-page":"4973","DOI":"10.1002\/cncr.24548","article-title":"Trends in survival after diagnosis with hematologic malignancy in adolescence or young adulthood in the United States, 1981\u20132005","volume":"115","author":"Pulte","year":"2009","journal-title":"Cancer"},{"issue":"24","key":"10.1016\/bs.acc.2019.11.002_bb9385","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1182\/blood-2014-11-551481","article-title":"How I treat acute lymphoblastic leukemia in older adolescents and young adults","volume":"125","author":"Curran","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1016\/bs.acc.2019.11.002_bb9390","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s11899-018-0442-1","article-title":"Recent developments in adolescent and young adult (AYA) acute lymphoblastic leukemia","volume":"13","author":"Orellana-Noia","year":"2018","journal-title":"Curr. Hematol. Malig. Rep."},{"issue":"5","key":"10.1016\/bs.acc.2019.11.002_bb9395","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.hoc.2009.07.004","article-title":"Looking toward the future: novel strategies based on molecular pathogenesis of acute lymphoblastic leukemia","volume":"23","author":"Abutalib","year":"2009","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/bs.acc.2019.11.002_bb9400","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1756-8722-6-40","article-title":"Novel agents and biomarkers for acute lymphoid leukemia","volume":"6","author":"Zhao","year":"2013","journal-title":"J. Hematol. Oncol."},{"issue":"5","key":"10.1016\/bs.acc.2019.11.002_bb9405","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.hoc.2009.07.009","article-title":"Risk-adapted treatment of pediatric acute lymphoblastic leukemia","volume":"23","author":"Jeha","year":"2009","journal-title":"Hematol. Oncol. Clin. North Am."},{"issue":"2","key":"10.1016\/bs.acc.2019.11.002_bb9410","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3324\/haematol.2009.011346","article-title":"Clinical features and prognostic implications of TCF3-PBX1 and ETV6-RUNX1 in adult acute lymphoblastic leukemia","volume":"95","author":"Burmeister","year":"2010","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/bs.acc.2019.11.002_bb9415","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.3324\/haematol.2011.059584","article-title":"Excellent prognosis of late relapses of ETV6\/RUNX1-positive childhood acute lymphoblastic leukemia: lessons from the FRALLE 93 protocol","volume":"97","author":"Gandemer","year":"2012","journal-title":"Haematologica."},{"issue":"5","key":"10.1016\/bs.acc.2019.11.002_bb9420","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.cancergen.2013.04.004","article-title":"Chromosomal translocations involving the IGH@ locus in B-cell precursor acute lymphoblastic leukemia: 29 new cases and a review of the literature","volume":"206","author":"Chapiro","year":"2013","journal-title":"Cancer Genet."},{"issue":"14","key":"10.1016\/bs.acc.2019.11.002_bb9425","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1200\/JCO.2013.51.3242","article-title":"IGH@ translocations are prevalent in teenagers and young adults with acute lymphoblastic leukemia and are associated with a poor outcome","volume":"32","author":"Russell","year":"2014","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"9617","key":"10.1016\/bs.acc.2019.11.002_bb9430","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0140-6736(08)60457-2","article-title":"Acute lymphoblastic leukaemia","volume":"371","author":"Pui","year":"2008","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/bs.acc.2019.11.002_bb9435","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1365-2141.2010.08246.x","article-title":"Prognostic factors in adult acute lymphoblastic leukaemia","volume":"150","author":"Rowe","year":"2010","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/bs.acc.2019.11.002_bb9440","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1182\/blood.V71.1.123.123","article-title":"Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults","volume":"71","author":"Hoelzer","year":"1988","journal-title":"Blood"},{"issue":"12","key":"10.1016\/bs.acc.2019.11.002_bb9445","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1182\/blood-2005-04-1623","article-title":"Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII\/ECOG E2993","volume":"106","author":"Rowe","year":"2005","journal-title":"Blood"},{"issue":"4","key":"10.1016\/bs.acc.2019.11.002_bb9450","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S1470-2045(15)70082-3","article-title":"Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study","volume":"16","author":"Pui","year":"2015","journal-title":"Lancet Oncol."},{"issue":"26","key":"10.1016\/bs.acc.2019.11.002_bb9455","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.1182\/blood-2012-07-444042","article-title":"Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia","volume":"120","author":"Faham","year":"2012","journal-title":"Blood"}],"container-title":["Advances in Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S006524231930099X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S006524231930099X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T19:38:05Z","timestamp":1758742685000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S006524231930099X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"ISBN":["9780128211663"],"references-count":89,"URL":"https:\/\/doi.org\/10.1016\/bs.acc.2019.11.002","relation":{},"ISSN":["0065-2423"],"issn-type":[{"type":"print","value":"0065-2423"}],"subject":[],"published":{"date-parts":[[2020]]}}}